As the influence of a wider range of stakeholders increasingly impacts drug development, what are the best ways to find the right people and start a meaningful dialogue? Andrew Butcher explores this in PharmaPhorum. To read the article, click the link below.
Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
Davis discussed the transition from obesity-specific opt-in benefits to more standard coverage. She expects that payers will need to handle a wider range of...